To evaluate reduction in number of lesions in disseminated cysticercosis after 2 weeks of albendazole with whole body MRI -A Pilot Study
Not Applicable
- Conditions
- Health Condition 1: G998- Other specified disorders of nervous system in diseases classified elsewhereHealth Condition 2: B608- Other specified protozoal diseases
- Registration Number
- CTRI/2020/04/024815
- Lead Sponsor
- Kinzang Wangda
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All the cases of disseminated cyscticercosis.
Patients of neurocysticercosis will be diagnosed on the basis of Del Brutto criteria.
Disseminated cysticercosis will be diagnosed as presence of multiple, (three or more than three) cystic viable lesions in the brain along with involvement of an additional extra site.
Exclusion Criteria
Patient in cysticercal encephalitis.
The patients having evidence of systemic illness such as primary malignancy,HIV,Hepatitis B and C virus, pulmonary and systemic tuberculosis.
Patients/ attendants refusing consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate reduction in number of cysticercus lesions after 2 weeks of albendazole.Timepoint: Three months
- Secondary Outcome Measures
Name Time Method To evaluate for symptomatic improvement after the therapy.Timepoint: patients will be followed up on monthly basis.